{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,12]],"date-time":"2025-09-12T18:31:46Z","timestamp":1757701906105},"reference-count":69,"publisher":"Oxford University Press (OUP)","issue":"954","license":[{"start":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T00:00:00Z","timestamp":1112313600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>This review focuses on the modern management of the non-ST elevation acute coronary syndromes (unstable angina and non-ST elevation myocardial infarction). Patients with these syndromes are at varying degrees of risk of (re)infarction and death. This risk can be reliably predicted by clinical, electrocardiographic, and biochemical markers. Aspirin, clopidogrel, heparin (unfractionated or low molecular weight), and anti-ischaemic drugs should be offered to all patients, irrespective of the predicted level of risk. Patients at high risk should also receive a glycoprotein IIb\/IIIa receptor inhibitor and should undergo early coronary arteriography with a view to percutaneous or surgical revascularisation. Lower risk patients should undergo non-invasive testing. When inducible myocardial ischaemia is exhibited coronary arteriography should follow. When non-invasive testing is negative, a conservative management strategy is safe.<\/jats:p>","DOI":"10.1136\/pgmj.2004.022590","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T18:14:14Z","timestamp":1112724854000},"page":"217-222","source":"Crossref","is-referenced-by-count":3,"title":["Contemporary management of acute coronary syndrome"],"prefix":"10.1093","volume":"81","author":[{"given":"G A","family":"Large","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,4,5]]},"reference":[{"key":"2023042408265345400_R1","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0735-1097(85)80036-X","article-title":"Sequence of mechanical, electrocardiographic and clinical effects of repeated coronary artery occlusion in human beings: echocardiographic observations during coronary angioplasty","volume":"5","author":"Hauser","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(94)91161-4","article-title":"Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients","volume":"343","author":"Fibrinolytic Therapy Trialists\u2019 (FTT) Collaborative Group","year":"1994","journal-title":"Lancet"},{"key":"2023042408265345400_R3","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1001\/jama.1997.03550230069040","volume":"278","author":"Weaver","year":"1997","journal-title":"JAMA"},{"key":"2023042408265345400_R4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1001\/jama.284.7.835","article-title":"The TIMI risk score for unstable angina\/non-ST elevation MI: A method for prognostication and therapeutic decision making","volume":"284","author":"Antman","year":"2000","journal-title":"JAMA"},{"key":"2023042408265345400_R5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1053\/euhj.2001.2738","article-title":"An integrated clinical approach to predicting the benefit of tirofiban in non-ST elevation acute coronary syndromes. Application of the TIMI risk score for UA\/NSTEMI in PRISM-PLUS","volume":"23","author":"Morrow","year":"2002","journal-title":"Eur Heart J"},{"key":"2023042408265345400_R6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","article-title":"Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection. Fragmin in Unstable Coronary Artery Disease (FRISC) Study Group","volume":"29","author":"Lindahl","year":"1997","journal-title":"J Am Coll Card"},{"key":"2023042408265345400_R7","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1056\/NEJM200106213442501","article-title":"Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb\/IIIa inhibitor tirofiban","volume":"344","author":"Cannon","year":"2001","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R8","first-page":"133","article-title":"British Cardiac Society Guidelines and Medical Practice Committee and Royal College of Physicians Clinical Effectiveness and Evaluation Unit","volume":"85","author":"Anonymous. Guideline for the management of patients with acute coronary syndromes without persistent ECG ST segment elevation","year":"2001","journal-title":"Heart"},{"key":"2023042408265345400_R9","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1053\/euhj.2002.3385","volume":"23","author":"Bertrand","year":"2002","journal-title":"Eur Heart J"},{"key":"2023042408265345400_R10","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0735-1097(00)00889-5","volume":"36","author":"Braunwald","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R11","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S0735-1097(02)02336-7","article-title":"ACC\/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology\/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina)","volume":"40","author":"Braunwald","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R12","doi-asserted-by":"crossref","first-page":"S353","DOI":"10.1016\/S0002-8703(98)70265-0","article-title":"TIMI 11B. Enoxaparin versus unfractionated heparin for unstable angina or non-Q-wave myocardial infarction: a double-blind, placebo-controlled, parallel-group, multicenter trial, Rationale, study design, and methods. Thrombolysis in Myocardial Infarction (TIMI) 11B Trial Investigators","volume":"135","author":"Antman","year":"1998","journal-title":"Am Heart J"},{"key":"2023042408265345400_R13","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1161\/01.CIR.80.2.410","article-title":"Unstable angina. A classification","volume":"80","author":"Braunwald","year":"1989","journal-title":"Circulation"},{"key":"2023042408265345400_R14","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/0735-1097(95)00009-S","article-title":"Incidence and follow-up of Braunwald subgroups in unstable angina pectoris","volume":"25","author":"van Miltenburg-van Zijl","year":"1995","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R15","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1161\/01.CIR.90.1.613","article-title":"Diagnosing and managing unstable angina. Agency for Health Care Policy and Research","volume":"90","author":"Braunwald","year":"1994","journal-title":"Circulation"},{"key":"2023042408265345400_R16","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0002-9149(02)02701-7","article-title":"Prognosis in the thrombolysis in myocardial ischemia III registry according to the Braunwald unstable angina pectoris classification","volume":"90","author":"Scirica","year":"2002","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S0735-1097(97)00160-5","article-title":"The electrocardiogram predicts one-year outcome of patients with unstable angina and non-Q wave myocardial infarction: results of the TIMI III registry ECG ancillary study. Thrombolysis in myocardial ischemia","volume":"30","author":"Cannon","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R18","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1053\/euhj.2001.2694","article-title":"ST depression in ECG at entry indicates severe coronary lesions and large benefits of an early invasive treatment strategy in unstable coronary artery disease; the FRISC II ECG substudy. The fast revascularisation during instability in coronary artery disease","volume":"23","author":"Diderholm","year":"2002","journal-title":"Eur Heart J"},{"key":"2023042408265345400_R19","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/S0735-1097(02)02824-3","article-title":"Troponin T and quantitative ST-segment depression offer complementary prognostic information in the risk stratification of acute coronary syndrome patients","volume":"41","author":"Kaul","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1111\/j.1365-2796.1993.tb00746.x","article-title":"Very early risk stratification by electrocardiogram at rest in men with suspected unstable coronary heart disease. The RISC Study Group","volume":"234","author":"Nyman","year":"1993","journal-title":"J Intern Med"},{"key":"2023042408265345400_R21","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1093\/clinchem\/45.7.1104","article-title":"National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery diseases","volume":"45","author":"Wu","year":"1999","journal-title":"Clin Chem"},{"key":"2023042408265345400_R22","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1056\/NEJM199610313351801","article-title":"Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA Investigators","volume":"335","author":"Ohman","year":"1996","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R23","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1161\/01.CIR.93.9.1651","article-title":"Relation between troponin T and the risk of subsequent cardiac events in unstable coronary artery disease. The FRISC study group","volume":"93","author":"Lindahl","year":"1996","journal-title":"Circulation"},{"key":"2023042408265345400_R24","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S0002-9149(99)80274-4","article-title":"Prognostic value of cardiac troponin T in unstable angina pectoris","volume":"76","author":"Wu","year":"1995","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R25","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199610313351802","article-title":"Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes","volume":"335","author":"Antman","year":"1996","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R26","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(99)10285-X","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban. PRISM Study Investigators. Platelet receptor inhibition in ischemic syndrome management","volume":"354","author":"Heeschen","year":"1999","journal-title":"Lancet"},{"key":"2023042408265345400_R27","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1056\/NEJMoa011053","article-title":"The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes","volume":"345","author":"de Lemos","year":"2001","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R28","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0002-9149(96)90386-0","article-title":"Prognostic value of plasma fibrinogen concentration in patients with unstable angina and non-Q-wave myocardial infarction (TIMI IIIB trial)","volume":"78","author":"Becker","year":"1996","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R29","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1161\/01.CIR.96.12.4204","article-title":"Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease","volume":"96","author":"Toss","year":"1997","journal-title":"Circulation"},{"key":"2023042408265345400_R30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0002-9149(97)00493-1","article-title":"Long-term low-molecular-weight heparin (Fragmin) and\/or early revascularization during instability in coronary artery disease (the FRISC II study)","volume":"80","author":"Wallentin","year":"1997","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R31","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0735-1097(00)00581-7","article-title":"Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment trial","volume":"35","author":"Heeschen","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R32","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0195-668X(02)00322-6","article-title":"Elevated troponin T and C-reactive protein predict impaired outcome for 4 years in patients with refractory unstable angina, and troponin T predicts benefit of treatment with abciximab in combination with PTCA","volume":"24","author":"Lenderink","year":"2003","journal-title":"Eur Heart J"},{"key":"2023042408265345400_R33","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1056\/NEJMoa022600","article-title":"Soluble CD40 ligand in acute coronary syndromes","volume":"348","author":"Heeschen","year":"2003","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R34","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1056\/NEJM198810273191701","article-title":"Aspirin, heparin, or both to treat acute unstable angina","volume":"319","author":"Theroux","year":"1988","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R35","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1161\/01.CIR.88.5.2045","article-title":"Aspirin versus heparin to prevent myocardial infarction during the acute phase of unstable angina","volume":"88","author":"Theroux","year":"1993","journal-title":"Circulation"},{"key":"2023042408265345400_R36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","author":"Anonymous","year":"2002","journal-title":"BMJ"},{"key":"2023042408265345400_R37","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1056\/NEJMoa010746","volume":"345","author":"Yusuf","year":"2001","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R38","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1161\/01.CIR.0000029926.71825.E2","article-title":"Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups","volume":"106","author":"Budaj","year":"2002","journal-title":"Circulation"},{"key":"2023042408265345400_R39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0140-6736(98)06113-3","article-title":"Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb\/IIIa blockade. Evaluation of platelet IIb\/IIIa inhibitor for stenting","volume":"352","author":"The EPISTENT Investigators","year":"1998","journal-title":"Lancet"},{"key":"2023042408265345400_R40","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1056\/NEJM199706123362401","article-title":"Platelet glycoprotein IIb\/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization","volume":"336","author":"The EPILOG Investigators","year":"1997","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R41","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(96)10172-0","article-title":"Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to minimise platelet aggregation and coronary rhrombosis-II","volume":"349","author":"Anonymous","year":"1997","journal-title":"Lancet"},{"key":"2023042408265345400_R42","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/S0140-6736(96)10452-9","article-title":"Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study","volume":"349","author":"Anonymous","year":"1997","journal-title":"Lancet"},{"key":"2023042408265345400_R43","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1161\/01.CIR.96.5.1445","article-title":"Effects of platelet glycoprotein IIb\/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Randomized efficacy study of tirofiban for outcomes and restenosis","volume":"96","author":"The RESTORE Investigators","year":"1997","journal-title":"Circulation"},{"key":"2023042408265345400_R44","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1056\/NEJM199404073301402","article-title":"Use of a monoclonal antibody directed against the platelet glycoprotein IIb\/IIIa receptor in high-risk coronary angioplasty","volume":"330","author":"The EPIC Investigation","year":"1994","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0140-6736(02)07442-1","volume":"359","author":"Boersma","year":"2002","journal-title":"Lancet"},{"key":"2023042408265345400_R46","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/S0003-4975(00)01654-4","article-title":"Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: results from PURSUIT. Platelet glycoprotein IIb\/IIIa in unstable angina: receptor suppression using integrelin therapy","volume":"70","author":"Dyke","year":"2000","journal-title":"Ann Thorac Surg"},{"key":"2023042408265345400_R47","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1161\/01.CIR.102.24.2952","article-title":"Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting. PURSUIT Investigators","volume":"102","author":"Marso","year":"2000","journal-title":"Circulation"},{"key":"2023042408265345400_R48","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/S0140-6736(00)05060-1","article-title":"Effect of glycoprotein IIb\/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial","volume":"357","author":"Simoons","year":"2001","journal-title":"Lancet"},{"key":"2023042408265345400_R49","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1001\/jama.1996.03540100055028","article-title":"Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis","volume":"276","author":"Oler","year":"1996","journal-title":"JAMA"},{"key":"2023042408265345400_R50","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0140-6736(96)91270-2","article-title":"Low-molecular-weight heparin during instability in coronary artery disease","volume":"347","author":"Fragmin During Instability in Coronary Artery Disease (FRISC) Study Group","year":"1996","journal-title":"Lancet"},{"key":"2023042408265345400_R51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0002-9149(98)00108-8","article-title":"Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and safety of subcutaneous enoxaparin versus intravenous unfractionated heparin, in non-Q-wave coronary events","volume":"82","author":"Cohen","year":"1998","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R52","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1161\/01.CIR.100.15.1602","article-title":"Assessment of the treatment effect of enoxaparin for unstable angina\/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis","volume":"100","author":"Antman","year":"1999","journal-title":"Circulation"},{"key":"2023042408265345400_R53","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1001\/jama.1988.03410150107041","article-title":"Overview of results of randomized clinical trials in heart disease. II. Unstable angina, heart failure, primary prevention with aspirin, and risk factor modification","volume":"260","author":"Yusuf","year":"1988","journal-title":"JAMA"},{"key":"2023042408265345400_R54","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1016\/S0002-9149(83)80117-9","article-title":"Intravenous nitroglycerin for the treatment of angina at rest unresponsive to standard nitrate therapy","volume":"51","author":"Kaplan","year":"1983","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R55","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1111\/j.1445-5994.1982.tb02645.x","article-title":"Intravenous nitroglycerine in refractory unstable angina pectoris","volume":"12","author":"Roubin","year":"1982","journal-title":"Aust N Z J Med"},{"key":"2023042408265345400_R56","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0140-6736(95)90865-X","article-title":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction","volume":"345","author":"ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group","year":"1995","journal-title":"Lancet"},{"key":"2023042408265345400_R57","first-page":"1115","article-title":"Gruppo Italiano per lo Studio della Sopravvivenza nell\u2019infarto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction","volume":"343","year":"1994","journal-title":"Lancet"},{"key":"2023042408265345400_R58","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0735-1097(85)80400-9","article-title":"A randomized study comparing propranolol and diltiazem in the treatment of unstable angina","volume":"5","author":"Theroux","year":"1985","journal-title":"J Am Coll Cardiol"},{"key":"2023042408265345400_R59","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/0002-9149(86)90727-7","article-title":"Comparison of verapamil and propranolol therapy for angina pectoris at rest: a randomized, multiple-crossover, controlled trial in the coronary care unit","volume":"57","author":"Parodi","year":"1986","journal-title":"Am Cardiol"},{"key":"2023042408265345400_R60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0002-9149(00)00913-9","article-title":"Long-term effects of diltiazem and verapamil on mortality and cardiac events in non-Q-wave acute myocardial infarction without pulmonary congestion: post hoc subset analysis of the multicenter diltiazem postinfarction trial and the second Danish verapamil infarction trial studies","volume":"86","author":"Gibson","year":"2000","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0002-9149(87)90214-1","article-title":"Prognostic significance and beneficial effect of diltiazem on the incidence of early recurrent ischemia after non-Q-wave myocardial infarction: results from the multicenter diltiazem reinfarction study","volume":"60","author":"Gibson","year":"1987","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R62","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/0002-9149(91)90944-G","article-title":"Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish verapamil infarction trial (DAVIT-II) and other recent studies","volume":"67","author":"Yusuf","year":"1991","journal-title":"Am J Cardiol"},{"key":"2023042408265345400_R63","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1001\/jama.1995.03530080036038","article-title":"The risk of myocardial infarction associated with antihypertensive drug therapies","volume":"274","author":"Psaty","year":"1995","journal-title":"JAMA"},{"key":"2023042408265345400_R64","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S0140-6736(02)08265-X","volume":"359","author":"group","year":"2002","journal-title":"Lancet"},{"key":"2023042408265345400_R65","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1053\/euhj.1998.1354","article-title":"Cardioprotection by opening of the K(ATP) channel in unstable angina. Is this a clinical manifestation of myocardial preconditioning? Results of a randomized study with nicorandil. CESAR 2 investigation. Clinical European studies in angina and revascularization","volume":"20","author":"Patel","year":"1999","journal-title":"Eur Heart J"},{"key":"2023042408265345400_R66","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1161\/01.CIR.89.4.1545","article-title":"Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction. Results of the TIMI IIIB trial. Thrombolysis in myocardial ischemia","volume":"89","author":"Anonymous","year":"1994","journal-title":"Circulation"},{"key":"2023042408265345400_R67","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199806183382501","volume":"338","author":"Boden","year":"1998","journal-title":"N Engl J Med"},{"key":"2023042408265345400_R68","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S0140-6736(99)07349-3","article-title":"Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study","volume":"354","author":"Fragmin and Fast Revascularisation during Instability in coronary artery disease Investigators","year":"1999","journal-title":"Lancet"},{"key":"2023042408265345400_R69","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/S0140-6736(02)09894-X","article-title":"Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Randomized intervention trial of unstable angina","volume":"360","author":"Fox","year":"2002","journal-title":"Lancet"}],"container-title":["Postgraduate Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/81\/954\/217\/50025584\/postgradmedj-81-217.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/pmj\/article-pdf\/81\/954\/217\/50025584\/postgradmedj-81-217.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,24]],"date-time":"2023-04-24T08:31:00Z","timestamp":1682325060000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/pmj\/article\/81\/954\/217\/7031908"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,1]]},"references-count":69,"journal-issue":{"issue":"954","published-online":{"date-parts":[[2005,4,5]]},"published-print":{"date-parts":[[2005,4,1]]}},"URL":"https:\/\/doi.org\/10.1136\/pgmj.2004.022590","relation":{},"ISSN":["0032-5473","1469-0756"],"issn-type":[{"value":"0032-5473","type":"print"},{"value":"1469-0756","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2005,4]]},"published":{"date-parts":[[2005,4,1]]}}}